Evonik Industries (XTRA:EVK) Posted Mixed Q2 Earnings, Is The Valuation Gap Too Wide?
Mixed second quarter earnings for Evonik Industries
Evonik Industries (XTRA:EVK) reported second quarter 2026 earnings with sales of €3,893 million compared to €3,499 million a year earlier. Net income was €84 million versus €120 million, highlighting higher revenue but weaker profitability.
See our latest analysis for Evonik Industries.
Evonik Industries’ 1 month share price return of 7.38% and year to date share price return of 35.54% point to building momentum, while the 5 year total shareholder return of 14.28% shows a weaker longer term picture despite the more recent 1 year total shareholder return of 15.04% and 3 year total shareholder return of 22.92%.
If earnings have you reassessing where growth and risk are shifting, it can be helpful to broaden your search and look at 104 top founder-led companies
The recent 1 month share price gain and the wide implied discount to fair value put Evonik Industries in an interesting spot. Is the market rightly cautious after weaker profits, or has the reaction gone too far on price?
Most Popular Narrative: 1.5% Overvalued
Against the last close of €18.04, the most followed narrative for Evonik Industries points to a fair value of about €17.78, suggesting only a small valuation gap and a finely balanced outlook.
Ongoing portfolio shift towards high-margin specialty chemicals and away from commoditized businesses aligns with strict regulatory trends and customer demands for eco-friendly, high-value additives, supporting both top-line growth and structural margin uplift over the long term.
Read the complete narrative. Read the complete narrative.
Want to see what sits behind that small premium to fair value? The core narrative leans on steadier margins, measured revenue growth and a future earnings profile that must justify a lower valuation multiple than many current sector peers.
Result: Fair Value of €17.78 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Evonik Industries still faces key risks, including weaker demand in cyclical sectors and ongoing exposure to lower margin commodity chemicals, which could challenge the current fair value story.
Find out about the key risks to this Evonik Industries narrative.
Another View on Evonik Industries’ Valuation
The earlier narrative framed Evonik Industries as only about 1.5% above its €17.78 fair value, which points to a fairly tight range around the current €18.04 share price. Our DCF model presents a different view, with a value of €69.68 and a large implied discount.
If one method suggests Evonik is finely priced while the SWS DCF model shows a wide gap, which set of assumptions do you find more convincing as you weigh the risks?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Evonik Industries for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on Evonik Industries finely balanced between concern and optimism, now is a good time to review the numbers yourself and decide where you stand. To see both sides of the story in one place, start with 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Evonik Industries?
If Evonik Industries has sharpened your focus, do not stop here. Broadening your watchlist with fresh stock ideas can help you spot opportunities earlier.
- Target dependable income potential by checking out 438 dividend fortresses that may suit a dividend-focused approach.
- Hunt for quality at a sensible price with the 257 high quality undervalued stocks before other investors start paying attention.
- Prioritise resilience by scanning the 297 resilient stocks with low risk scores and see which stocks score well on overall risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com